Saturday, 07 December 2019

Clinical trials for Prima BioMed's CVacâ„¢ extended

24 April 2014 | News | By BioSpectrum Bureau

Australian Biotech major Prima BioMed is said to have extended its clinical trials on CVacâ„¢

Australian Biotech major Prima BioMed is said to have extended its clinical trials on CVacâ„¢

Singapore: Prima BioMed, Australia's leading biotechnology company pioneering in therapeutic area of cancer is said to be extending clinical trials of CVacTM.

On Monday, the company is said to have made the decision to extend the clinical trials of CVacTM, which is its flagship product candidate

The company's shares are in a trading hald, pending the announcement that is said to be made on June 26, Wednesday.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is APAC region emerging as a leader in assistive technologies?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls